STEAP1B

Across TCGA pan-cancer cohorts, STEAP1B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STEAP1B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher STEAP1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STEAP1B expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

GBM, UCEC, and PDAC are the cancer types where STEAP1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.628	0.801	.001	18	view →
UCEC	DFS	Quartile	All	1.000	0.753	.001	16	view →
PDAC	OS	Tertile	II,III,IV	0.282	0.531	.011	12	view →
LSCC	OS	Median	All	0.199	0.901	.045	3	view →
HNSC	DFS	Median	III,IV	0.878	0.541	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STEAP1B–GBM (DFS)

Open the GBM breakdown →